Premium
Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppurativa
Author(s) -
Provini Lauren E.,
Stellar Judith J.,
Stetzer Molly N.,
Nguyen Phuong D.,
Jen Melinda
Publication year - 2019
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.13775
Subject(s) - hidradenitis suppurativa , medicine , ustekinumab , hyperbaric oxygen , refractory (planetary science) , dermatology , combination therapy , adalimumab , tumor necrosis factor alpha , surgery , disease , physics , astrobiology
Hidradenitis suppurativa is a painful chronic inflammatory skin condition characterized by inflammatory nodules that can lead to sinus tracts and scarring. Numerous treatments have been reported, though none have reliable efficacy. Antiinflammatory agents, such as tumor necrosis factor‐alpha inhibitors and interleukin inhibitors, have been used as medical therapy for refractory cases. We describe here a case of severe hidradenitis suppurativa in a pediatric patient successfully treated with a combination of high‐dose ustekinumab and hyperbaric oxygen therapy.